# Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

> **NCT04331093** · PHASE2 · RECRUITING · sponsor: **Di Wu** · enrollment: 40 (estimated)

## Conditions studied

- Acral Melanoma

## Interventions

- **DRUG:** SHR-1210+Apatinib

## Key facts

- **NCT ID:** NCT04331093
- **Lead sponsor:** Di Wu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-01
- **Primary completion:** 2024-12
- **Final completion:** 2026-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04331093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04331093, "Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04331093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*